Goldman upgraded Align Tech from Sell to Neutral and set a new price target of $307.00 from $165.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2024 | Hold | Needham | |
| 2/26/2024 | $310.00 | Market Perform | Leerink Partners |
| 12/11/2023 | $197.00 | Neutral → Sell | Goldman |
| 10/27/2023 | $200.00 | Buy → Neutral | UBS |
| 2/2/2023 | $165.00 → $307.00 | Sell → Neutral | Goldman |
| 7/28/2022 | $380.00 → $250.00 | Buy → Sell | Goldman |
| 2/3/2022 | $782.00 → $722.00 | Outperform | Credit Suisse |
| 2/3/2022 | $675.00 → $625.00 | Buy | Stifel |
10-Q - ALIGN TECHNOLOGY INC (0001097149) (Filer)
8-K - ALIGN TECHNOLOGY INC (0001097149) (Filer)
8-K - ALIGN TECHNOLOGY INC (0001097149) (Filer)
4 - ALIGN TECHNOLOGY INC (0001097149) (Issuer)
4 - ALIGN TECHNOLOGY INC (0001097149) (Issuer)
4 - ALIGN TECHNOLOGY INC (0001097149) (Issuer)
Needham initiated coverage of Align Tech with a rating of Hold
Leerink Partners initiated coverage of Align Tech with a rating of Market Perform and set a new price target of $310.00
Goldman downgraded Align Tech from Neutral to Sell and set a new price target of $197.00
4 - ALIGN TECHNOLOGY INC (0001097149) (Issuer)
4 - ALIGN TECHNOLOGY INC (0001097149) (Issuer)
4 - ALIGN TECHNOLOGY INC (0001097149) (Issuer)
Company expects to repurchase up to $275.0 million of its common stock beginning in Q4'24 Q3'24 total revenues of $977.9 million, increased 1.8% year-over-year, and Q3'24 diluted net income per share was $1.55, or $2.35 on a non-GAAP diluted basis Q3'24 total revenues were unfavorably impacted by foreign exchange by approximately $14.6 million year-over-year(1), and were not significantly impacted sequentially Q3'24 operating income of $162.3 million and operating margin of 16.6%, non-GAAP operating margin of 22.1% Q3'24 GAAP operating margin was unfavorably impacted by foreign exchange by approximately 0.8 points year-over-year(1), and was not significantly impacted sequentially
Align Technology, Inc. (NASDAQ:ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report third quarter 2024 financial results on Wednesday, October 23, 2024, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com. Following the press release, Align will host a conference call to discuss its financial results. The conference call will be
Align Technology, Inc. (NASDAQ:ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report second quarter 2024 financial results on Wednesday, July 24, 2024, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com. Following the press release, Align will host a conference call to discuss its financial results. The conference call will be
SC 13G/A - ALIGN TECHNOLOGY INC (0001097149) (Subject)
SC 13G/A - ALIGN TECHNOLOGY INC (0001097149) (Subject)
SC 13G/A - ALIGN TECHNOLOGY INC (0001097149) (Subject)
Align Technology, Inc. (NASDAQ:ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced it has appointed Emory Wright, executive vice president, direct fabrication manufacturing platform, effective immediately. Mr. Wright will transition his current responsibilities for global operations, including treatment planning, and focus on scaling Align's next generation direct fabrication manufacturing platform, working in close collaboration with Srini Kaza, who was promoted to executive vice president, res
Align Technology, Inc. (NASDAQ:ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that after nearly six years with Align, Yuval Shaked, executive vice president and managing director of iTero scanner and services, has decided to leave the company for personal reasons and spend more time with his family. He will remain with Align and continue as a member of Align Technology President and CEO Joe Hogan's staff supporting strategic initiatives and programs through 2023. Mr. Shaked will transition
TEMPE, Ariz., SAN JOSE, Calif., and SINGAPORE, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Align Technology, Inc. (NASDAQ:ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Raj Pudipeddi, Align Technology chief product and marketing officer, and senior vice president will assume additional responsibility for the commercial organization in the Asia Pacific region as managing director, effective immediately, succeeding Julie Tay, Align Technology senior vice president and managing director, Asia Pacifi
Stifel analyst Jonathan Block maintains Align Tech (NASDAQ:ALGN) with a Buy and lowers the price target from $400 to $350.
Piper Sandler analyst Jason Bednar maintains Align Tech (NASDAQ:ALGN) with a Overweight and lowers the price target from $330 to $315.
Invisalign® Palatal Expanders offer doctors a removeable, safe, and clinically effective alternative to traditional palatal expanders. With Invisalign First™ aligners and Invisalign® Palatal Expanders, Align Technology now provides doctors with a full early intervention treatment solution, including both skeletal (orthopedic) and dental (orthodontic) arch expansion. The Invisalign Palatal Expander System has also completed registration with the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA). Both approvals are for broad patient applicability, including growing children, teens, and adults (with surgery or other techniques). Align Technology, Inc. ("Ali
Align Technology, Inc. ("Align") (NASDAQ:ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from the 2024 Invisalign Ortho Summit, Align's premier clinical education and peer-to-peer networking experience designed to help doctors transform and grow their practice with Invisalign® clear aligners, iTero scanners, and the Align™ Digital Platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241111839157/en/ The 2024 Invisalig
2025 Grant Application Process Now Open for Up to $300,000 in Funding Align Technology, Inc. (NASDAQ:ALGN) today announced the opening of its 2025 Annual Research Award Program to support clinical and scientific dental research in universities across the globe. This year, up to $300,000 will be awarded to university faculty for scientific and technological research initiatives to advance patient care in the fields of orthodontics and dentistry. Align Technology's Research Award Program has funded approximately $3.75 million in research since the program's inception in 2010. "This program continues to generate much scientific and clinical interest from university researchers around the glo